For the year ending 2025-12-31, AEON had $2,993K increase in cash & cash equivalents over the period. -$17,312K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | -39,222 |
| Depreciation | 78 |
| Stock-based compensation expense | 5,317 |
| Non-cash issuance of common stock | 250 |
| Loss on issuance of warrants | -75,644 |
| Change in fair value of convertible notes | -22,911 |
| Change in fair value of warrants | -84,934 |
| Loss on derivative liability | 13,088 |
| Change in fair value of contingent consideration | -3,499 |
| Prepaid expenses and other current assets | -1,185 |
| Accounts payable | -4,968 |
| Accrued expenses and other liabilities | -2,206 |
| Other assets and liabilities | 952 |
| Net cash used in operating activities | -17,308 |
| Purchases of property and equipment | 4 |
| Net cash used in investing activities | -4 |
| Proceeds from issuance of shares, net-At Market Offering | 168 |
| Proceeds from issuance of public offering shares, net-Public Offering | 18,346 |
| Proceeds from issuance of shares, net-Private Placement | 1,791 |
| Net cash provided by financing activities | 20,305 |
| Net decrease in cash | 2,993 |
| Cash and cash equivalent at beginning of period | 13 |
| Cash and cash equivalent at end of period | 3,006 |
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)